Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy

•Subgroup analysis of a non-interventional study in adenocarcinoma NSCLC.•Outcomes with nintedanib plus docetaxel after chemo- and immunotherapy (n = 67).•Nintedanib plus docetaxel given in third- or later-lines in 57 patients (85.1%).•Clinical effectiveness demonstrated: DCR was 78.2% and median OS was 8.8 months.•Provides real-world data to inform management in the changing treatment landscape.